Physician profile
Daniel Roling
NPI 1285659425
$4,255.07
in general payments reported to CMS, 2019-2025
19 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $346 · 2021: $390 · 2022: $554 · 2023: $301 · 2024: $342 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,425 · Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,425.00 |
| Food and Beverage | $1,088.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,500.34 | 2019-2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $618.69 | 2019-2025 | |
| Leo Pharma As | $450.00 | 2022 | |
| Genzyme Corporation | $372.42 | 2021 | |
| Dr.Reddy'S Laboratories,INC. | $325.00 | 2019 | |
| Abbvie INC. | $306.62 | 2022-2025 | Skyrizi |
| Cepheid | $303.00 | 2020 | |
| Pfizer INC. | $105.07 | 2022-2025 | |
| Strata Skin Sciences, INC. | $52.53 | 2024-2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $42.91 | 2023-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $36.08 | 2021-2023 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $26.67 | 2025 | Sotyktu |
| Incyte Corporation | $20.95 | 2024 | Opzelura |
| Janssen Biotech, INC. | $20.72 | 2023 | Tremfya |
| Galderma Laboratories, L.P. | $19.44 | 2025 | Nemluvio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.21 | 2025 | Otezla |
| Biofrontera INC. | $13.11 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $12.16 | 2022 | |
| Merck Sharp & Dohme LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Roling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.